Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Current Liabilities (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Total Current Liabilities for 13 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 40.62% to $13.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.5 million through Dec 2025, up 40.62% year-over-year, with the annual reading at $12.6 million for FY2025, 146.18% up from the prior year.
  • Total Current Liabilities hit $13.5 million in Q4 2025 for Vistagen Therapeutics, down from $13.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $13.6 million in Q3 2025 to a low of $2.9 million in Q3 2023.
  • Historically, Total Current Liabilities has averaged $7.2 million across 5 years, with a median of $6.3 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: crashed 84.88% in 2021 and later soared 158.57% in 2024.
  • Year by year, Total Current Liabilities stood at $6.4 million in 2021, then crashed by 33.23% to $4.3 million in 2022, then fell by 2.87% to $4.2 million in 2023, then skyrocketed by 131.02% to $9.6 million in 2024, then soared by 40.62% to $13.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for VTGN at $13.5 million in Q4 2025, $13.6 million in Q3 2025, and $11.2 million in Q2 2025.